Retatrutide in 2026: FDA Timeline, Expanded Access, and Real Cost

The five questions people are actually asking about retatrutide in 2026

Search data across the last 90 days shows one pattern: patients are not waiting for peer-reviewed literature — they're typing bare, specific questions into Google.

1. When will retatrutide be FDA approved?
2. How much will it cost?
3. Can I get it now?
4. What is the dosing schedule?
5. How is the "reta" being sold online different?

This guide answers all five with the current public record as of August 2026.

1. FDA timeline — Q1 2027 filing, decision likely 2027 or 2028

The most important date for retatrutide is Q1 2027. On July 23, 2026, Eli Lilly announced that two additional Phase 3 trials met their endpoints and confirmed it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027.

Reuters confirmed the same filing window, noting Lilly is completing its Chemistry, Manufacturing, and Controls (CMC) data package before submitting.

What that means in practice:

• Q1 2027: BLA submission
• ~10-12 months: Standard FDA review window
• Late 2027 – 2028: Possible decision window (if the application is accepted for review and no additional data is requested)

The FDA has granted retatrutide Fast Track designation for obesity, which allows for more frequent communication with the sponsor and rolling review. Priority Review — a six-month rather than ten-month review clock — has not been formally granted, and Lilly has not publicly confirmed it will request it.

Bottom line: If you're waiting on retail-pharmacy retatrutide, plan for late 2027 at the earliest, more likely 2028.

2. What will retatrutide cost? Context from the current GLP-1 market

Lilly has not announced a retatrutide list price. It won't until FDA approval and commercial launch. But the current GLP-1 pricing landscape gives us realistic benchmarks.

What retatrutide is likely to cost: Post-approval, expect a list price in the same $1,000 – $1,400/month range as other GLP-1s. Real patient cost will depend on:

• Insurance coverage: Some commercial plans cover obesity GLP-1s; Medicare Part D coverage varies.
• Manufacturer savings cards: Zepbound's savings card currently brings commercially-insured patients to ~$25/month; Lilly will likely offer similar for retatrutide.
• Direct-pay channels: Programs like TrumpRx and LillyDirect may offer cash-pay pricing near $300-$400/month.

Nobody knows the actual retatrutide launch price yet. Anyone quoting one is guessing.

3. Can I get retatrutide right now? Only two legitimate paths

Two — and only two — legitimate ways to access authentic retatrutide exist in August 2026.

Path 1: Expanded Access Program

Lilly's expanded-access program opened in August 2026 for a narrow group of adults with refractory obesity. See our detailed page: Retatrutide Expanded Access Program: Who Qualifies.

The public eligibility criteria require:

• Age 18 or older
• Refractory obesity with BMI ≥35 despite the highest available chronic weight-management therapy
• At least two serious or life-threatening obesity-related complications under standard care
• Inability to enroll in an ongoing relevant clinical trial
• Documented discussion of standard options, including bariatric surgery
• No medical contraindication to retatrutide

The process is physician-led. A treating clinician must contact Lilly on the patient's behalf. Meeting the criteria does not guarantee access.

Path 2: Enroll in a Phase 3 clinical trial

The TRIUMPH Phase 3 program includes several trials still recruiting or enrolling as of mid-2026. Search "retatrutide" on ClinicalTrials.gov, filter to "Recruiting" or "Not yet recruiting" status, and contact the study sites directly.

Trial participation typically includes:

• Free study medication
• Regular monitoring by trial staff
• Structured protocol (you may receive placebo depending on trial design)

What is NOT a legitimate path

Retatrutide sold through peptide websites, med spas, compounding pharmacies, or "research chemical" vendors is not authentic Lilly product. On August 12, 2026, Lilly filed six lawsuits against U.S. entities selling these products. See our Authentic vs Counterfeit Retatrutide Safety Guide for details.

4. Retatrutide dosing schedule from Phase 3 trials

Retatrutide is administered as a once-weekly subcutaneous injection. The Phase 3 trial titration schedule steps up every four weeks:

Three maintenance doses were tested in Phase 3: 4 mg, 8 mg, and 12 mg weekly. Higher doses produced more weight loss but also higher rates of GI side effects.

For a visual walkthrough of the titration schedule, see our Retatrutide Trial Dose Visualizer.

5. Expected weight loss — what Phase 3 actually showed

In the TRIUMPH Phase 3 program, retatrutide produced the highest average weight loss reported for any GLP-1 to date:

For comparison, tirzepatide (Zepbound) delivered ~20.9% at 72 weeks and semaglutide (Wegovy) delivered ~14.9% at 68 weeks in their respective Phase 3 programs.

Full head-to-head comparisons: retatrutide vs tirzepatide, retatrutide vs semaglutide.

6. Why "reta" being sold online is a completely different thing

This is the single most important point in this guide.

The retatrutide molecule is real. The Phase 3 data is real. Lilly's clinical trial supply is real.

None of that means a vial you buy from a peptide website is the same substance.

When you order "retatrutide" online, all you can verify is the name on the label. You cannot verify:

• Identity — that the powder actually is retatrutide
• Potency — that the amount matches the label
• Sterility — that it hasn't been contaminated
• Chain of custody — where it was actually made

Lilly's August 12, 2026 statement and the FDA's warning to health care professionals both say the same thing: unapproved retatrutide products may be contaminated, may contain too much or too little of the active ingredient, or may be counterfeit products that contain none at all.

For the deep breakdown of red flags: Authentic vs Counterfeit Retatrutide Safety Guide.

What to do while you wait

If retatrutide is approved on the earliest realistic timeline (late 2027), that's still 14+ months away. Here's what makes sense in the meantime:

If you have obesity with medical complications

1. Ask your physician about the expanded-access program.
2. Search ClinicalTrials.gov for active retatrutide trials.
3. Consider currently-approved options — oral or injectable GLP-1s — with your clinician.

If you have obesity without additional complications

1. Expanded access is unlikely to apply. Focus on currently-approved options.
2. Explore direct-pay pricing for Zepbound, Mounjaro, and Wegovy if insurance doesn't cover.
3. Read the 2026 GLP-1 Playbook for maximizing current-drug results.

If you're considering online "reta"

Don't. Read our safety guide and understand what you're risking. The molecule is real, but what's in the vial isn't verifiable.

What to watch for in the next 12 months

• Q4 2026: Full TRIUMPH readouts and additional Phase 3 sub-analyses.
• Q1 2027: Expected BLA filing.
• Q1-Q2 2027: FDA acceptance of the application (or a Refuse-to-File letter, unlikely but possible).
• Late 2027 – early 2028: Possible advisory committee meeting (obesity drugs often skip AdComs).
• Late 2027 – 2028: Possible FDA decision date (PDUFA date).

We'll update this page as milestones are reached.

Sources

• Eli Lilly Investor Release, July 23, 2026 — Q1 2027 BLA plan
• Reuters, July 23, 2026 — Lilly Q1 2027 FDA application plan
• Eli Lilly Press Release, August 12, 2026 — Six lawsuits against black-market sellers
• Washington Post, August 12, 2026 — Lawsuit coverage
• White House Fact Sheet, November 2025 — TrumpRx GLP-1 pricing benchmarks
• ClinicalTrials.gov — Retatrutide trials
• FDA — Fast Track Designation program